STENTYS Self-Apposing Stents in "Perfect Apposition to Vessels” after Treating Patients with Heart Attacks

Regulatory News:

"APPOSITION I” study published in leading medical journal EuroIntervention

STENTYS S.A. (Paris:STNT) (STNT.PA), a medical technology company that is commercializing the world's first and only self-apposing stent to treat Acute Myocardial Infarction (AMI), announced today the publication of the results of the "APPOSITION I” clinical study results in the September issue of the medical journal EuroIntervention,

The study showed that the STENTYS Self-Apposing Stent enabled the perfect apposition of these stents when treating patients with AMI. The self-apposing feature of the STENTYS stent ensures optimal apposition during thrombus and vessel spasm relief in the critical initial hours and days after an AMI procedure, thereby avoiding malapposition, a significant concern to cardiologists.

"We continue to be very pleased with the results of the STENTYS Self-Apposing Stent when treating AMI,” said Dr. Giovanni Amoroso, OLVG Hospital (Amsterdam, the Netherlands) and lead author of the article. "During the six-month follow-up period of the APPOSITION I study, there was no death, no stent thrombosis or reoccurrence of MI, with revascularization rates comparable to that of conventional stents.”

Prestigious medical journal EuroIntervention (www.eurointervention.org) is the official publication of EuroPCR and the European Association of Percutaneous Cardiovascular Interventions (EAPCI) and is endorsed by The European Society of Cardiology (ESC).

About STENTYS

Based in Princeton, N.J., and Paris, STENTYS has developed a new generation of stents to treat acute myocardial infarction (AMI). Founded by Jacques Séguin, M.D., Ph.D., (also founder of CoreValve, which was acquired by Medtronic) and Gonzague Issenmann, STENTYS received CE-marking for its flagship products in 2010. Its Self-Apposing Stent adapts to the anatomic changes of the artery in the post-infarction phase and thus prevents the malapposition problem associated with conventional stents. STENTYS has marketing activities in several European countries.

This announcement is not an offer for sale of securities in the United States. The securities referred to herein have not been offered or sold in the United States and may not be offered or sold in the United States of America, except pursuant to a registration statement under the U.S. Securities Act of 1933, as amended (the "Securities Act"), or pursuant to an exemption from registrations thereunder. This press release is being issued pursuant to and in accordance with Rule 135c under the Securities Act.